Sanofi with New MENA Strategy!

Some one year back I wrote about companies like Merck and Novartis opening their shop floors in Turkey and how Turkey going forward is becoming a hot destination  for drug marketing and promotion, in a recent progress Sanofi is looking for acquisition of Czech company Zentiva which is worth $2.6 Billion , the deal will help Sanofi accelerate its presence in the MENA region as Zentiva has strong presence in the region….last month there were update for Biosimilar development by companies for MENA region…..after India and China ……MENA is the next favorable destination going forward

MENA: Middle East and North Africa

Will these two drugs save Pfizer????

In year 2012 I will consider November as the best month for Pfizer as it has got approval for two important drugs which the analyst and the scientists believe that will mark a difference for Pfizer in terms of the blockbuster game, though now a days in the pharma world more than the blockbuster image it’s the overall maintenance of the market value....... Pfizer got approval for its two major products where in the market is very lucrative.......Tofacitinib and Eliquis are a class drug in their own way but will both these drugs be able to reach Lipitor sales status as expected....only time will say? 

J&J......will it be there in the race?

J&J is a company to watch for....being the company with one of the best credo's available till date with it vision and mission in place for more than 150 years, though there have been so many changes going around but this company has always been one of pioneers with good pipeline and products in the market. What I am still not able to understand is that why this company has not gone ahead for its biosimilar development...As everyone has joined the rat race, what is J&J going to do?

Like the other giant who have been all over the place, I though that by 2012 J&J will be part of the game and will announce but I think my hopes will not turn into reality soon.

RNAi the bubble era!!

Last decade we heard, read and wrote about RNAi technology....every one used to say we have one technology which will hit into the granular level, there were many deals which were happening in this segment, from year 2005 to 2010 there were significant number of deals in this segment but somehow the bubble has faded away....Not many companies are talking about it..Last two years I have not seen many major deals happening in this segment and some biggies have even scrapped their projects... still companies and scientists are doing research but we are still in the hope that this technology will bear some fruits in the coming years....I hope our dream turns into a reality and we have some direct hit products in the market soon in next coming 5 years........

Pfizer: Will it still retain it position as gobal leader position!

During my B.pharma years I did my internship in Orgenon India, followed by Dey's medical, a good experience of working in a manufacturing plant where in you have GMP compliances. At that point of time Pfizer was taking over Warner pharma and then I started looking at this big companies history and series of merger and acquisitions. Both Novartis and Pfizer have a very hyper competitive environment; my view point has been developed after series of discussions with ex employs of both of this organization. Pfizer was also the first company where in I joined for marketing rep position in year 2001.

Pfizer blockbuster lipitor became off patent last year and this year Pfizer has good hope for Tofacitinib for which average sales is expected to be $2.2 Bn...But if we look at the company's pipeline they do not have extensive pipeline like some scientific global companies. So strategy going forward for Pfizer is to buy late stage molecules. Now time will say that late stage compound buy outs will help it to still maintain its global position or its going to lose its market to hyper aggressive competitor Novartis

Cloud computing!

Last time I wrote about how Pfizer is looking for options of using Cloud computing, the question which creeps in my mind every time i read about cloud is that if cloud is really the safest mode of storage. I was looking into the news which was published in the earlier part of this week, French giant Sanofi Aventis has gone for options of cloud computing for its clinical datasets and data management.


Already more than 25 companies in and around the globe have gone for cloud computing as data storage option but is it going to the most safest option for the Pharma companies, it’s a food for thought......and if the companies are looking for options of managing their clinical trial update, should they believe that there data in cloud is really safe?

Biotech....still has bright future?

2005 to 2008 we observed the largest number of deals in Biotechnology front, but after the recession there were very less number of deals, acquisition and partnership in this front, but analyst are still having the hope that 2013 we will have more number of deals in the Biotechnology front...As there is a lot of speculation that by 2020 the market for biologics in expected to be 60 Billion USD and the Biosimilar will capture market of more than $6 Billion. We need to see....last week we heard that Amgen has gone ahead to start with a new biotech startup and Novartis like its competitors in establishing its Biological unit in South Asia...

As last year J&J, Roche have already gone ahead to form their base, after china, Singapore as biotech hub, will India become the next biotech hub going forward?

But will this Biotech boom exist in Asia for long as it has started fading away from its sunshine in US and Europe?

New Drug Technologies!

Though at this point of time I am not doing any work related to my core expertise in which I had spent 4 years of my initial days......what is fascinating me now a days is that Bispecific and Antibody- Drug conjugates are the talk of the town, there are so many partnership deals happening in this space and we need to just see if Roche with its first Antoibody drug conjugate TDM1 will make the difference and will there be shift in the SOC. Roche with its correct strategies in place has monopolized the market and for the next 15-20 years secured its position in the space. Sometime I feel like going back to Research and start working again with some new technologies.